These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 11242497

  • 1. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.
    ACE Inhibitors in Diabetic Nephropathy Trialist Group.
    Ann Intern Med; 2001 Mar 06; 134(5):370-9. PubMed ID: 11242497
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2000 Mar 06; (2):CD002183. PubMed ID: 10796871
    [Abstract] [Full Text] [Related]

  • 5. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.
    Lancet; 1997 Jun 21; 349(9068):1787-92. PubMed ID: 9269212
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. WITHDRAWN: Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2007 Jul 18; (1):CD002183. PubMed ID: 17636698
    [Abstract] [Full Text] [Related]

  • 10. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ.
    Diabet Med; 2011 Oct 18; 28(10):1182-7. PubMed ID: 21627686
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG.
    Cochrane Database Syst Rev; 2001 Oct 18; (1):CD002183. PubMed ID: 11279757
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.
    Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R.
    Diabetes Care; 1998 Jan 18; 21(1):104-10. PubMed ID: 9538979
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
    Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong LA, Fuller JH.
    Diabetes; 1998 Sep 18; 47(9):1507-11. PubMed ID: 9726242
    [Abstract] [Full Text] [Related]

  • 18. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, Glasziou P, Neil A, Dunger D, M Colhoun H, Pugh C, Wong G, Perera R, Shine B.
    Health Technol Assess; 2014 Feb 18; 18(14):1-128. PubMed ID: 24576414
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C.
    Lancet Diabetes Endocrinol; 2017 Aug 18; 5(8):610-621. PubMed ID: 28666775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.